VANCOUVER, BC / ACCESSWIRE / October 23, 2019 / Else Nutrition Holdings Inc. (TSX.V:BABY) (OTCQB:BABYF)(“Else” or the “Company“), a company focused on developing and marketing a real alternative to dairy-based infant nutrition, is pleased to announce that effective October 1, 2019, Dr. Jon A. Vanderhoof has been appointed to the Advisory Board of Else Nutrition GH Ltd., the Company’s operating company which is located in Israel..
“We are extremely pleased to add Dr. Vanderhoof’s experience and insights to the Else Nutrition Team. His extensive expertise, particularly in children’s health and nutrition will be of tremendous benefit to our company and our customers,” said Hamutal Yitzhak, CEO of Else Nutrition. She added, “His passion for improving children’s health perfectly complements our vision as we move our product towards commercialization.”
“The opportunity to join Else Nutrition in their vision to create clean-label, and nutritious plant-based alternatives for infants, toddlers and children is extremely exciting. Many of today’s parents are demanding all-natural, plant-based solutions free of antibiotics, GMO, and hormones, for their children’s nutrition. Careful formulation and scientific and clinical evaluation of such products are essential to ensure their safety and efficacy,” said Dr. Vanderhoof. He added, “Else Nutrition’s breakthrough formulation will provide the safety and assurance parents need to optimize their child’s health and well-being, and I look forward to helping extend this impact.”
Dr. Vanderhoof is a pediatric gastroenterologist in at Boston Children’s Hospital, Senior Lecturer in Pediatrics at the Harvard Medical School, and Professor Emeritus of Pediatrics at the University of Nebraska College of Medicine. He was the first Chief of Pediatric Gastroenterology and Nutrition at the University of Nebraska Medical Center and served as Chair of Pediatrics at Creighton University. Dr. Vanderhoof was Vice President, Global Medical Affairs and Chief Medical Officer, for Mead Johnson Nutrition from 2002 to 2011. Dr. Vanderhoof received his medical degree from the University of Nebraska College of Medicine, completed his fellowship in Pediatric Gastroenterology and Nutrition at the University of California at Los Angeles, and has been in practice for over 20 years.
Dr. Vanderhoof has published over 200 peer-reviewed papers, reviews and literature in various areas of pediatric gastroenterology and nutrition. He served as President of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition and on the editorial boards of numerous scientific and clinical journals. He has lectured widely both nationally and internationally on a variety of issues related to all areas of pediatric gastrointestinal disease and nutrition. Dr. Vanderhoof received the Shwachman Award in 2001 from the North American Society of Pediatric Gastroenterology and Nutrition, the highest award given in the field of Pediatric Gastroenterology in North America.
About Else Nutrition Holdings Inc.
Else Nutrition Holdings Inc. (TSX.V:BABY) (OTCQB:BABYF)(“Else” or the “Company“). The Company is a food and nutrition company focused on research, development, manufacturing, marketing, sale and/or license of innovative plant-based food and nutrition products to the infant, toddler, children and adult markets. Its revolutionary 100% plant-based non-soy alternative to dairy-based baby formula received the “Best Health and Diet Solutions” award in the Global Food Innovation Summit in Milan in May 2017. For more information, visit: elsenutrition.com.
TSX Venture Exchange
Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Statements
This press release contains statements that, to the extent they are not recitations of historical fact, constitute “forward-looking statements” within the meaning of applicable securities legislation. Forward-looking statements are typically identified by words such as “will”, “plan” or similar expressions. Forward-looking statements in this press release include, but are not limited to, statements with respect to: the Company’s commercialization of its products, the relevance of personnel’s work experience, and industry conditions.
Such forward-looking statements reflect current estimates, beliefs and assumptions, which are based on management’s perception of historical trends, current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. No assurance can be given that the foregoing will prove to be correct.
Forward-looking statements made in this press release assume, among others, the successful completion of Else’s proposed scale-up for its products, and such statements are intended to apply only to the infant formula market for ages 12 months and above, and having all necessary regulatory approval as required by each target market.
Numerous risks and uncertainties could cause the Company’s actual results to differ materially from the estimates, beliefs and assumptions expressed or implied in the forward-looking statements, including, but not limited to: consumer demand for the Company’s products, whether the Company’s current and future products achieve commercialization, uncertainty regarding material changes in laws and regulations, retention of key personnel, the Company’s ability to expand into global markets and competitive developments.
The foregoing list of factors is not exhaustive, and other risks and uncertainties not presently known, or believed to be material, to management Additional information and other factors that could affect the operations or financial results of the Company are set out in the Company’s Filing Statement dated May 14, 2019 under the heading “Risk Factors” and may be accessed through the SEDAR website (www.sedar.com).
Readers are cautioned not to place undue reliance on any forward-looking statements, which reflect management’s expectations only as of the date of this press release. The Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.